Parkinson disease (PD) is the second most common neurodegenerative disorder, affecting>
1% of the population≥ 65 years of age and with a prevalence set to double by 2030. In …

Objective To update evidence‐based medicine recommendations for treating nonmotor
symptoms in Parkinson's disease (PD). Background The International Parkinson and …

Neurodegenerative diseases pose a substantial socioeconomic burden on society.
Unfortunately, the aging world population and lack of effective cures foreshadow a negative …

Dementia is a frequent problem encountered in advanced stages of Parkinson disease (PD).
In recent years, research has focused on the pre-dementia stages of cognitive impairment in …

The spectrum of cognitive decline in the elderly ranges from what can be classified as
normal cognitive decline with aging to subjective cognitive impairment to mild cognitive …

Objective The goal of this contribution is to gather and to critically analyze recent evidence
regarding the potential of exergaming for Parkinson's disease (PD) rehabilitation and to …

Affective disorders, cognitive decline, and psychosis have long been recognized as common
in Parkinson disease (PD), and other psychiatric disorders include impulse control …

Cognitive impairment occurs in most individuals with Parkinson's disease (PD), exacting a
high toll on patients, their caregivers, and the healthcare system. In this review, we begin by …

Quinazolines are considered as a promising class of bioactive heterocyclic compounds with
broad properties. Particularly, the quinazoline scaffold has an impressive role in the design …

Cognitive impairment risk in Parkinson's disease increases with disease progression and
poses a significant burden to the patients, their families and society. There are no disease …